Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Dividends

Explore dividend yields, payout ratios, and historical trends to maximize your investment strategies.

Last Close
May 23 02:25PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)- Insider Own27.83% Shs Outstand25.52M Perf Week-1.94%
Market Cap38.79M Forward P/E- EPS next Y-0.38 Insider Trans0.00% Shs Float18.42M Perf Month7.80%
Income- PEG- EPS next Q- Inst Own3.58% Short Float0.43% Perf Quarter2.70%
Sales- P/S- EPS this Y34.43% Inst Trans- Short Ratio1.12 Perf Half Y-9.52%
Book/sh- P/B- EPS next Y5.00% ROA- Short Interest0.08M Perf Year-0.46%
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range0.92 - 3.07 Perf YTD-14.12%
Dividend Est.- P/FCF- EPS past 5Y-53.58% ROI- 52W High-50.49% Beta0.03
Dividend TTM- Quick Ratio- Sales past 5Y0.00% Gross Margin- 52W Low65.20% ATR (14)0.09
Dividend Ex-Date- Current Ratio- EPS Y/Y TTM- Oper. Margin- RSI (14)54.30 Volatility6.32% 5.75%
Employees- Debt/Eq- Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price7.00
Option/ShortNo / Yes LT Debt/Eq- EPS Q/Q-39.29% Payout- Rel Volume0.04 Prev Close1.49
Sales Surprise- EPS Surprise- Sales Q/Q- Earnings- Avg Volume71.28K Price1.52
SMA201.98% SMA503.41% SMA200-8.22% Trades Volume2,072 Change1.80%
May-08-24 07:00AM
Apr-30-24 07:00AM
Apr-08-24 07:00PM
Apr-02-24 07:00AM
Mar-22-24 07:00AM
07:00AM Loading…
Mar-21-24 07:00AM
Mar-20-24 07:00AM
Feb-09-24 07:00AM
Jan-31-24 07:00AM
Jan-08-24 07:00AM
Jan-05-24 09:30AM
Dec-04-23 07:00AM
Oct-31-23 07:00AM
Oct-09-23 07:00AM
Oct-05-23 07:00AM
07:00AM Loading…
Sep-15-23 07:00AM
Sep-14-23 09:15AM
Sep-13-23 04:05PM
Sep-08-23 07:00AM
Aug-30-23 07:00AM
Aug-29-23 07:00AM
Aug-15-23 09:00AM
Jul-31-23 02:18AM
Jul-28-23 05:25PM
Jul-27-23 11:30AM
Jun-06-23 09:30AM
May-11-23 07:00AM
08:45AM Loading…
May-09-23 08:45AM
May-04-23 01:22PM
May-03-23 02:00AM
May-02-23 02:00AM
Apr-25-23 02:00AM
Apr-18-23 10:00AM
OKYO Pharma Ltd. operates as a biopharmaceutical company, which engages in the development of therapeutics for inflammatory eye diseases and chronic pain. It operates through the US and UK geographical segments. The company was founded on July 4, 2007 and is headquartered in London, the United Kingdom.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BRANCACCIO JOHN PDirectorSep 15 '23Buy1.5016,67025,00516,670Sep 28 06:15 AM